Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Current Treatment Options in Oncology

Volumn 19, Issue 1, 2018, Pages

  Gill, David M ^a,b   Hahn, Andrew W ^c   Hale, Peter ^c   Maughan, Benjamin L ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b Division of Hematology   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Checkpoint inhibitors; Immunotherapy; Metastatic clear cell renal cell carcinoma; mTOR inhibitors; Predictive biomarkers; VEGF TKIs

Indexed keywords

ALPHA INTERFERON; ATEZOLIZUMAB; AVELUMAB; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CHECKPOINT KINASE INHIBITOR; EPACADOSTAT; EVEROLIMUS; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2; IPILIMUMAB; LENVATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NIVOLUMAB; PAZOPANIB; PEMBROLIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; VASCULOTROPIN INHIBITOR; ANILIDE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ARTICLE; CANCER CENTER; CANCER PATIENT; CANCER RISK; CLEAR CELL CARCINOMA; COMORBIDITY; DIARRHEA; EASTERN COOPERATIVE ONCOLOGY GROUP; HUMAN; HYPERTENSION; IMMUNOTHERAPY; KIDNEY MATASTASIS; KIDNEY METASTASIS; KIDNEY METASTATIS; LEUKOPENIA; METASTATIC CLEAR CELL RENAL CELL CARCINOMA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RENAL CELL CARCINOMA; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; KIDNEY TUMOR; METASTASIS; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

ANILIDES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUNITINIB; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85040950741     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-018-0517-1     Document Type: Article

References (59)

1. Cho E, Adami HO, Lindblad P. Epidemiology of renal cell cancer. Hematol Oncol Clin North Am. 2011;25(4):651–65. https://doi.org/10.1016/j.hoc.2011.04.002.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75. https://doi.org/10.1056/NEJM199609193351207.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am. 2003;30(4):843–52. https://doi.org/10.1016/S0094-0143(03)00056-9.
4. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl 1):S55–7.
5. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000;27(2):187–93.
6. Albiges L, Escudier B. Current and future strategies in nonclear-cell metastatic renal cell carcinoma. Curr Opin Urol. 2015;25(5):367–73. https://doi.org/10.1097/MOU.0000000000000197.
7. Giles RH, Choueiri TK, Heng DY, et al. Recommendations for the management of rare kidney cancers. Eur Urol. 2017.
8. Valenca LB, Hirsch MS, Choueiri TK, Harshman LC. Non-clear cell renal cell carcinoma, part 1: histology. Clin Adv Hematol Oncol. 2015;13(5):308–13.
9. Valenca LB, Hirsch MS, Choueiri TK, Harshman LC. Non-clear cell renal cell carcinoma, part 2: therapy. Clin Adv Hematol Oncol. 2015;13(6):383–91.
10. Network CGAR. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43.
11. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32. https://doi.org/10.1016/S0140-6736(09)60229-4.
12. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A. 1996;93(20):10589–94. https://doi.org/10.1073/pnas.93.20.10589.
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. https://doi.org/10.1056/NEJMoa060655.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. https://doi.org/10.1056/NEJMoa065044.
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81. https://doi.org/10.1056/NEJMoa066838.
16. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56. https://doi.org/10.1016/S0140-6736(08)61039-9.
17. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11. https://doi.org/10.1016/S0140-6736(07)61904-7.
18. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8. https://doi.org/10.1200/JCO.2009.23.9764.
19. Rini B, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol. 2011;29(15_suppl):4503. https://doi.org/10.1200/jco.2011.29.15_suppl.4503.
20. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–23. https://doi.org/10.1056/NEJMoa1510016.
21. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. https://doi.org/10.1016/S1470-2045(15)00290-9.
22. Pal SK, Nelson RA, Vogelzang N. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One. 2013;8(5):e63341. https://doi.org/10.1371/journal.pone.0063341.
23. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665.
24. Choueiri T, Hessel C, Halabi S, et al. LBA38Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). Ann Oncol 28, 2017. Phase 2 trial reporting superioer PFS for cabozantinib over sunitinib in the first-line setting for patients with IMDC intermediate or poor risk mRCC.
25. Escudier B, Tannir N, McDermott D, et al: LBA5CheckMate 214: Efficacy and safety of nivolumab+ ipilimumab (N+ I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Ann Oncol 28, 2017. Phase 3 trial reporting superior PFS, ORR, and OS for patients treated with nivolumab and ipilimumab compared to sunitinib in the first-line setting for patients with IMDC intermediate or poor risk mRCC.
26. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161(5):1169–88. https://doi.org/10.1084/jem.161.5.1169.
27. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96. https://doi.org/10.1200/JCO.1995.13.3.688.
28. Clark JI, Wong MK, Kaufman HL, et al. Impact of sequencing targeted therapies with high-dose Interleukin-2 immunotherapy: an analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational IL-2 clinical trial: PROCLAIMSM. Clin Genitourin Cancer. 2017;15(1):31–41.e4. https://doi.org/10.1016/j.clgc.2016.10.008.
29. Alva A, Daniels GA, Wong MK, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer immunology. Immunotherapy. 2016;65(12):1533–44. https://doi.org/10.1007/s00262-016-1910-x.
30. Stenehjem DD, Toole M, Merriman J, et al: Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol, Immunotherapy:1–9, 2016.
31. Gills J, Parker WP, Pate S, et al: The role of high dose interleukin-2 in the Era of Targeted Therapy. J Urol. 2017.
32. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–8. https://doi.org/10.1200/JCO.2008.19.5511.
33. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90. https://doi.org/10.1200/JCO.2008.20.1293.
34. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31. https://doi.org/10.1056/NEJMoa1303989.
35. Ouzaid I, Rini B. Words of wisdom: re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Eur Urol. 2014;65(3):667–8. https://doi.org/10.1016/j.eururo.2013.11.023.
36. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412–8. https://doi.org/10.1200/JCO.2013.50.8267.
37. Ornstein MC, Wood LS, Elson P, et al. A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol:Jco2016711184, 2017.
38. Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, et al. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2014;92(3):208–17. https://doi.org/10.1016/j.critrevonc.2014.07.006.
39. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–50. https://doi.org/10.1200/JCO.2009.26.7849.
40. Flaherty KT, Manola JB, Pins M, et al. BEST: a randomized phase II study of vascular endothelial growth factor, raf kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—A trial of the ECOG–ACRIN Cancer Research Group (E2804). J Clin Oncol:JCO. 2015.60. 9727, 2015.
41. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–45. https://doi.org/10.1101/gad.1212704.
42. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66(11):5549–54. https://doi.org/10.1158/0008-5472.CAN-05-2825.
43. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015. J Natl Compr Cancer Netw. 2015;13(2):151–9. https://doi.org/10.6004/jnccn.2015.0022.
44. Ko JJ, Xie W, Kroeger N, Lee J, Rini BI, Knox JJ, et al. The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293–300. https://doi.org/10.1016/S1470-2045(14)71222-7.
45. Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol:JCO. 2013.54. 6911, 2014.
46. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol:JCO. 2016.70. 7398, 2016.
47. Atkins MB, McDermott DF, Powles T, et al. IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun), Am Soc Clin Oncol, 2017.
48. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, et al. Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunotherapy Cancer. 2015;3(1):14. https://doi.org/10.1186/s40425-015-0055-3.
49. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170–7. https://doi.org/10.1016/S1470-2045(13)70569-2.
50. Gill D, Hahn AW, Sonpavde G, Agarwal N. Immunotherapy of advanced renal cell carcinoma: current and future therapies. Hum Vaccin Immunother. 2016;12(12):2997–3004. https://doi.org/10.1080/21645515.2016.1212794.
51. Atkins M, Plimack E, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results. Eur Soc Med Oncol. 2016.
52. Lara P, Bauer TM, Hamid O, et al. Epacadostat plus pembrolizumab in patients with advanced RCC: preliminary phase I/II results from ECHO-202/KEYNOTE-037. Am Soc Clin Oncol. 2017.
53. Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2, 3-dioxygenase pathway in cancer. Journal for immunotherapy of cancer. 2015;3(1):51. https://doi.org/10.1186/s40425-015-0094-9.
54. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta Oncol. 2014;53(1):103–12. https://doi.org/10.3109/0284186X.2013.770600.
55. Beuselinck B, Jean-Baptiste J, Schoffski P, et al. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. BJU Int. 2016;118(6):890–901. https://doi.org/10.1111/bju.13585.
56. McDermott DF, Atkins MB, Motzer RJ, et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Am Soc Clin Oncol. 2017. Phase 2 trial reporting a trend toward improved PFS with combination atezolizumab and bevacizumab over sunitinib in the first-line setting for mRCC. Outcomes were improved in patients with positive PD-L1 staining
57. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5. https://doi.org/10.1158/0008-5472.CAN-05-4303.
58. Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016;22(10):2445–52. https://doi.org/10.1158/1078-0432.CCR-15-2631.
59. Lu H, Busch J, Jung M, Rabenhorst S, Ralla B, Kilic E, et al. Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. Clin Chim Acta. 2016;452:109–19. https://doi.org/10.1016/j.cca.2015.11.009.